U.S. Semiconductors Stock News

NasdaqGM:SMMT
NasdaqGM:SMMTBiotechs

Summit Therapeutics Enters FDA Review As Ivonescimab Trials Broaden Potential

Summit Therapeutics (NasdaqGM:SMMT) had its Biologics License Application for ivonescimab, in combination with chemotherapy, accepted by the US FDA for EGFR mutated advanced non squamous non small cell lung cancer after TKI therapy. The company is running several late stage clinical trials, and recent international Phase III results support expanding ivonescimab development beyond lung cancer. Ivonescimab is also being studied in colorectal cancer, reflecting broader pipeline ambitions...
NasdaqGS:TEAM
NasdaqGS:TEAMSoftware

Atlassian (TEAM) Q2 Loss Narrows To US$42.6m And Tests Profitability Narratives

Atlassian (TEAM) has just posted Q2 2026 results with revenue of US$1.6b and a basic EPS loss of US$0.16, alongside trailing twelve month revenue of US$5.8b and a basic EPS loss of US$0.72 that keeps the company in the red on a full year view. The company has seen quarterly revenue move from US$1.3b in Q2 2025 to US$1.6b in Q2 2026, while quarterly basic EPS over the same periods shifted from a loss of US$0.15 to a loss of US$0.16. This sets up this release as another checkpoint on how...